Global Blood Plasma Market Report: 2013 Edition- Koncept Analytics

View Report Details

Global Blood Plasma Market ------------------------------------------2013

View Report Details Executive Summary Plasma is a composite mixture of more than 700 proteins and other substances which are vital for the smooth functioning of the human body. Plasma is the liquid component of blood, constituting around 50% of the total blood volume. Plasma in itself is approximately 90% water, with the remaining 10% comprising of proteins, minerals, clotting factors, hormones, and immunoglobins. Plasma is the raw material for the extraction of various proteins which are used for their therapeutic values. Plasma proteins cannot be manufactured rather the same are obtained or collected from a large pool of donors.

With the swift progression in the field of biomedical/healthcare technology, companies operating in the healthcare/pharmaceutical/therapeutic industry are now surmounting in the respective realm. Also, on account of the escalating incidences of health related issues originating due to changing lifestyle and continuously changing surroundings, blood plasma industry’s growth is augmented. In order to address the unmet medical needs related to blood disorders, autoimmune diseases and liver function impairment among others, associated companies are coming up with novel and improved treatment options like IVIG, albumin, clotting factors etc. which are derived from human blood plasma.

The blood plasma industry is highly regulated to ensure the safety of collected plasma and protect donors. The market is characterized by fast pace developments in the clinical technology and testing methodology. This report elicits the global blood plasma market with focus on segmental markets like IVIG, albumin and hemophilia market. Also the regions including the US and China are covered. Moreover, market dynamics like the key trends, industry developments, growth drivers and challenges are analyzed in detail.

Furthermore, the competitive landscape of the industry is highlighted. The rivalry prevalent in the global blood plasma market is quite fierce with numerous local and global players contenting for the market share. On the global front, the key players are Baxter, CSL, Grifols and Octapharma.

The normal composition of human blood is: Plasma, Red Blood Cells (RBC), White Blood Cells (WBC) and Platelets…

Global Blood Plasma Market (2000-2011)

2011 2010 2009 2008 2007 2006 2005 2004 2003 2002 2001 2000

The global blood plasma market was valued at US$.......billion in 2010, and reached US$....... billion in 2011, depicting an increase of ……….% approximately. The recorded CAGR over the cited period was …….%. In terms of products, in 2011, the global blood plasma market was dominated by IVIGs or IGs with a significant share of ……..% followed by FVIII with …….% share. FIX and albumin constituted ……% share each. The plasma derivatives sales in the US stood at US$....... billion in 2011, witnessing an increase of …..% approximately over the value of US$......... billion in 2010. The manufacturing cost structure of plasma fractionation is such that the major portion of the cost, approximately …..%, is constituted by plasma product.

US$ Billion Plasma Derivative Sales in the US (2005-2011)

US$ Billion

Global Plasma Market Share by Product (2011)

2005

IG

Factor VIII

Factor IX

Albumin

Other Products

2006

2007

2008

2009

2010

2011

Plasma is the raw material for the extraction of various proteins. It can be divided into two categories depending on how it is obtained viz. Source plasma and Recovered plasma...

Global IVIG Market Size (2004-2011)

 As of 2011, the global sales of immunoglobulins stood at US$...... billion, registering a modest growth of …….% over the value of 2010.

For the period of 7 years spanning from 2004 to 2011, the global IVIG market recorded an impressive CAGR of …………%.

US$ Billion

 In terms of IVIG market size by volume, the US accounted for the maximum share with ……..tonnes of IVIG, followed by the EU with ……….tonnes of contribution in the global IVIG market as of 2011. In terms of value, the U.S. market was worth ……..billion approximately in 2011.  The IVIG market in the US stood at US$............billion in 2011, recording an increase of nearly ……..% over US$......... billion worth sales generated in 2010. The CAGR recorded over the cited period was ……..%.

2004

2005

2006

2007

2008

2009

2010

2011

Sales of IVIG in the US (2001-2011) IVIG Market Volume by Region (2005, 2008 and 2011)

Tonnes

US$ Billion

)

2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011

2005

2008 USA

EU

2011 RoW

In frozen condition, plasma can keep for up to 10 years, making it an extremely stable blood product.

Also, it can be packaged in dried form for reconstitution…

Global Plasma Market Share by Company (2011) Global Hemophilia Treatment Market Revenues (2006-2012)

2012 2011 2010 2009 2008 2007

Grifols Baxter Others- for profit

2006

CSL Octapharma Others- for non profit

US$ Billion

Albumin Market Size of the US and China

The global hemophilia treatment market revenues has been moving on an aggressive growth path, registering an increase of US$........billion to US$........billion by 2012 as compared to US$............ billion in 2006. As of October 2012, the albumin market of China was worth US$……. million while the same in the US was worth US$........million only.

US$ Million

As of 2011, the global plasma market was led by Grifols with 20% share, followed by CSL and Baxter with shares worth ……% and …..%, respectively. Octapharma accounted for ………% share in the same.

USA

China

The opportunity for global blood plasma market is anticipated to be US$...... billion for the year 2012. The respective market is poised to record a growth of ……% in 2012 as compared to the value of US$.......billion in 2011. The global blood plasma market is projected to grow at a CAGR of …….% over the period of three years spanning from 2012 to 2015 and estimated to reach US$.......... billion by the end of 2015.

Note: Market attractiveness is inverse of penetration. Low penetration means high attractiveness and vice-versa

Table of Contents

List of Charts & Tables

1. Overview

List of Charts

1.1 Components of Blood Plasma 1.2 Functions of Blood Plasma 1.3 Collection and Extraction of Plasma

Plasma Extraction from Donated Blood (Recovered Plasma) Plasmapheresis (Source Plasma) Global Blood Plasma Market (2000-2011) Global Plasma Market Share by Product (2011) Manufacturing Cost Split for Plasma Fractionation (September 2011) Plasma Derivative Sales in the US (2005-2011) US Source Plasma Collections (2007-2012E) Global IVIG Market Size (2004-2011) Global IVIG Demand and Supply (2007-2012E) IVIG Market Volume by Region (2005, 2008 and 2011) Global IVIG Market Share by Geography (2011) IVIG Use by Indication Sales of IVIG in the US (2001-2011) Global Hemophilia Treatment Market Revenues (2006-2012) Global FVIII Market (2011) Global FIX Market (2011) Annual Global Sales of NovoSeven (2007-2011) Monthly Distribution of FVIII in the US (January 2011-September 2012) Albumin Market Size of the US and China Albumin Price across US and China China’s Plasma Protein Market Growth (October 2012) Monthly Distribution of Albumin 25% in the US (January 2011-Sptember 2012) Monthly Distribution of Albumin 25% in the US (January 2011-Sptember 2012) Licensed Plasma Centers in the US and their profitability (FY06-FY11) A1PI Statistics of North America and EU Per Capita Usage of FVIII in Developed Countries Per Capita Usage of FVIII in Developing Countries Per Capita FIX Usage in Developed Economies Per Capita FIX Usage in Emerging Economies Global Healthcare Spending (2005-2015E) Global Spending on Medicines (2006-2016E) Global Spending on Medicine Share by Region (2006-2016E)

1.3.1 Plasma Collection 1.3.2 Plasma Extraction 1.3.3 Plasma Fractionation Yield 1.3.4 Plasma Usage 2. Blood Plasma Market Structure 2.1 Global Blood Plasma Market -Market Value -Market Segments 2.1.1 Plasma Industry Cost Structure 2.1.2 Plasma Market of the US 2.2 Global IVIG Market -Market Value -Demand & Supply -Breakdown by Region 2.2.1 IVIG Market of the US 2.3 Global Hemophilia Market -Hemophilia A -Hemophilia B

2.3.1 FVIII Market of the US 2.4 Albumin Market 2.4.1 Albumin Market of China and the US 3. Market Dynamics 3.1 Key Trends

3.1.1 Kinetics of Plasma-collection Industry 3.1.2 Reimbursement 3.1.3 Growing Penetration of rFVIII Products in Emerging Markets – Opportunity for Manufacturers 3.1.4 A1PI Deficiency- Confined to Prevention only

3.2 Industry Developments 3.2.1 Improved Biological Molecule Formulations 3.2.2 Baxter’s Phase I Clinical Trial of Treatment for Hemophilia A 3.3 Growth Drivers 3.3.1 Increasing New Patient Registration for Hemophilia Treatment 3.3.2 Increased Usage of Plasma Derived Products 3.3.3 Rising Healthcare Expenditure 3.3.4 Higher Spending on Medicines 3.3.5 Rising Demand for Better Healthcare Options 3.3.6 Launch of NMEs (New Molecular Entities) 3.3.7 Growing Ageing Population (+60 Years) 3.3.8 Rising Male Population 3.3.9 Ameliorating Economic Conditions 3.4 Challenges 3.4.1 Increasing regulation in the plasma-collection industry 3.4.2 Escalating Price Pressure 3.4.3 Constrained Plasma Fractionation Capacity 3.4.4 Misdiagnosis of the Disease

4. Competitive Landscape 4.1 Blood Plasma Market Rivalry 4.2 Plasma Derivatives Market Contention

4.2.1 Immunoglobulins -IVIG Market of Europe -IVIG Market of North America -IVIG Market of the US 4.2.2 Albumin Market -Albumin Market of the US

List of Charts The US Spending on Medicine (2007-2016E) Japan’s Spending on Medicine (2007-2016E) Biotechnology Therapeutics Under Development (2011) Global Ageing Population (2005-2013F) Global Male Population (2005-2014F) Global GDP (2001-2011) World GDP per Capita (2005-2011) Global Plasma Market Share by Company (2011) Aligned PCCs vs. independent PCCs Share in the US (2011) Europe’s IVIG Market Share (2011) North America’s IVIG Market Share (2011) US IVIG Market (2011) US Albumin Market Share (2011) China’s Albumin Market (2011-12) Product Rivalry in the US (2011) Baxter’s Revenue by Business Segments (2011) Baxter’s Revenues and Net Income (2008-2011) Grifols Revenue Share by Business Segments (2011) Grifols’ Revenues & Profits (2008-2011) CSL’s Revenue Share by Major Products (2011-12) CSL’s Revenues and Net Profit (2008/09-2011/12) Octapharma’s Net Sales and Net Profit (2008-2011) Global Blood Plasma Market Forecast (2009-2015F) List of Tables Constituents of Blood Plasma Recovered plasma vs. Source plasma Output per Liter of Plasma Breakdown of US IVIG usage by Patient Share & Volume Share by Indication Breakdown of US SCIG and IVIG Usage by Volume Share (FY11) US Centre for Medicare and Medicaid (CMS) Reimbursement Conversion to Recombinant Factor VIII Products in Selected Countries (2010) A1PI Products Long Acting FIX & FVIII under Late-Stage Development

-Albumin Market of China 4.2.3 Other Products 5. Company Profiles 5.1 Baxter International Inc. 5.1.1 Business Overview 5.1.2 Financial Overview 5.1.3 Business Strategies -Focus on Investment in R&D -Growth through Sustainable Development 5.2 Grifols 5.2.1 Business Overview 5.2.2 Financial Overview 5.2.3 Business Strategies -Expansion in Other Geographic Regions -Growth through Mergers and Acquisitions 5.3 CSL Limited 5.3.1 Business Overview 5.3.2 Financial Overview 5.3.3 Business Strategies -Focus on R&D -Expanding Product Portfolio

5.4 Octapharma 5.4.1 Business Overview 5.4.2 Financial Overview 5.4.3 Business Strategies -Focus on Innovation -Expansion of Production Facilities 6. Market Outlook 6.1 Market Forecast 6.2 Forecast Methodology 6.2.1 Dependent and Independent Variables 6.2.2 Correlation Analysis 6.2.3 Regression Analysis

List of Tables Extended Half Life rFVIII Agents Extended Half Life rFIX Agents New Patient Registrations in Worldwide Bleeding Disorders Market (20082013E) Patients Worldwide Waiting for Better Treatment Options (2011) Global Availability of NMEs (2011) IVIG Product Characteristics Dependent & Independent Variables (2007-2011) Correlation Matrix Regression Coefficients Output

View Report Contact Us:Details These are abridged and sanitized sample pages from the comprehensive report on the “Global Blood Plasma Market”. To know more about this report or for any customized research requirement, please contact the following:

Koncept Analytics

Vikas Gupta BD Manager

CS-36, Second Floor, Ansal Plaza Vaishali, Ghaziabad, U.P. – 201010 T. +91-120-4130959 C: +91-9811715635 vikas@konceptanalytics.com

www.konceptanalytics.com